Zydus Cadila said that its antiviral Virafin has been given emergency use authorisation by the Drug Controller General of India (DCGI) for treatment against coronavirus. The pharma company said that a single dose of the antiviral administered subcutaneously early on shows significant clinical and virological improvement in patients with moderate coronavirus. It stated that 91.15 per cent of patients who were treated with the antiviral were RT-PCR negative by Day 7. The treatment also reduces hours of supplemental oxygen in patients.
The company said that when administered early on during COVID-19, the Pegylated Interferon alpha-2b (PegIFN) Virafin will help patients recover faster and avoid many complications. The antiviral will be available on the prescription of medical specialists for use in hospital/institutional setups.
A multicentric trial was conducted in 20-25 centres across the nation that showed that with Virafin, patients required less supplemental oxygen. The company said that the trials indicate that the antiviral is able to control respiratory distress and failure that has been one of the biggest challenges in treating coronavirus. The drug also showed efficacy against other viral infections
Dr. Sharvil Patel, Managing Director, Cadila Healthcare said, "The fact that we are able to offer a therapy which significantly reduces viral load when given early on can help in better disease management. It comes at a much-needed time for patients and we will continue to provide them access to critical therapies in this battle against COVID-19."
During the Phase III clinical trials, patients administered with the drug were RT-PCR negative by Day 7. "The drug ensures faster viral clearance and has several add-on advantages compared to other antiviral agents," said the company.